市場調査レポート

商品コード

1790281

ナルトレキソンとブプレノルフィンの市場規模、シェア、動向分析レポート：製品別、投与経路別、用途別、流通チャネル別、地域別、セグメント別予測、2025年～2033年

Naltrexone And Buprenorphine Market Size, Share & Trends Analysis Report By Product (Naltrexone, Buprenorphine), By Route Of Administration, By Application, By Distribution Channel (Hospitals Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

出版日: 2025年07月03日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日

カスタマイズ可能

価格

Unprintable PDF & Excel (Single User License)

USD 5,950 889,703円

レポートPDF及びExcelを1名様のみがご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷はできません。

Printable PDF & Excel (5-User License)

USD 6,950 1,039,233円

レポートPDF及びExcelを同一企業内の同一部署における5名様までの方にご利用頂けるライセンスです。テキスト等のコピー＆ペースト、印刷は可能です。

Printable PDF & Excel (Enterprise License)

USD 8,950 1,338,293円

レポートの購入企業、およびその子会社、関連会社の方にご使用頂けるライセンスです。PDF及びExcelのテキスト等のコピー＆ペースト、印刷は可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=149.53円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ナルトレキソンとブプレノルフィン市場の概要

世界のナルトレキソンとブプレノルフィン市場規模は、2024年に41億7,000万米ドルと推定され、2033年には98億米ドルに達すると予測され、2025～2033年のCAGRは9.25%で成長すると予測されます。同市場は、物質使用障害の有病率の増加とオピオイド使用障害治療に対する意識の高まりにより成長が見込まれています。政府の取り組みにより、先進的中毒治療ソリューションへのアクセスがさらに増加しています。

WHOがオピオイド治療ガイドラインを更新

2025年2月、世界保健機関（WHO）は、効果的な介入へのアクセスを拡大するため、オピオイド依存治療と過剰摂取予防に関するガイドラインを更新しました。改訂されたガイドラインでは、オピオイド依存に対する最も効果的な治療法として、メタドンまたはブプレノルフィンによるオピオイド作動薬維持療法（OAMT）の重要性が強調されました。WHOはまた、特に地域社会での過剰摂取による死亡を防ぐために、ナロキソンをより広く利用できるようにすることを推奨しました。新しいガイダンスは、規制上の障壁を減らし、薬害軽減サービスへの投資を増やすよう求めました。さらに、ヘルスケア提供者に対し、エビデンスに基づいた、患者中心、差によるないケアを提供するよう求めました。これらの勧告は、増加するオピオイド関連の健康課題に対処し、世界的に公衆衛生の成果を向上させるために、各国を支援することを目的としています。

地域別市場シェア分析、2024年と2033年
地域別市場ダッシュボード
市場規模と予測動向分析、2021～2033年
北米
- 国別、2021～2033年
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- デンマーク
- スウェーデン
- ノルウェー
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- タイ
ラテンアメリカ
- ブラジル
- アルゼンチン
中東・アフリカ
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- クウェート

第9章競合情勢

参加者概要
企業の市況分析
企業分類
戦略マッピング
企業プロファイル/上場企業
- Indivior PLC
- Collegium Pharmaceutical（BioDelivery Sciences International, Inc.）
- Alkermes, Inc.
- Orexo US, Inc.（a part of Orexo AB）
- Titan Pharmaceuticals, Inc.
- Omeros Corporation
- Camurus
- Sun Pharmaceutical Industries Ltd

図表

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Naltrexone and buprenorphine market, by region, 2021 - 2033 (USD Million)
Table 4 Global Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 5 Global Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 6 Global Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 7 Global Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 8 North America Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 9 North America Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 10 North America Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 11 North America Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 12 North America Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 13 U.S. Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 14 U.S. Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 15 U.S. Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 16 U.S. Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 17 Canada Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 18 Canada Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 19 Canada Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 20 Canada Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 21 Mexico Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 22 Mexico Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 23 Mexico Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 24 Mexico Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 25 Europe Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 26 Europe Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 27 Europe Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 28 Europe Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 29 Europe Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 30 UK Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 31 UK Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 32 UK Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 33 UK Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 34 Germany Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 35 Germany Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 36 Germany Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 37 Germany Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 38 France Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 39 France Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 40 France Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 41 France Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 42 Italy Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 43 Italy Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 44 Italy Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 45 Italy Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 46 Spain Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 47 Spain Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 48 Spain Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 49 Spain Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 50 Norway Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 51 Norway Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 52 Norway Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 53 Norway Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 54 Denmark Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 55 Denmark Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 56 Denmark Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 57 Denmark Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 58 Sweden Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 59 Sweden Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 60 Sweden Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 61 Sweden Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 62 Asia Pacific Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 63 Asia Pacific Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD
Table 64 Asia Pacific Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 65 Asia Pacific Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 66 Asia Pacific Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 67 Japan Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 68 Japan Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 69 Japan Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 70 Japan Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 71 China Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 72 China Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 73 China Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 74 China Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 75 India Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 76 India Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 77 India Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 78 India Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 79 Australia Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 80 Australia Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 81 Australia Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 82 Australia Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 83 South Korea Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 84 South Korea Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 85 South Korea Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 86 South Korea Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 87 Thailand Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 88 Thailand Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 89 Thailand Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 90 Thailand Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 91 Latin America Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 92 Latin America Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 93 Latin America Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 94 Latin America Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 95 Latin America Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 96 Brazil Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 97 Brazil Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 98 Brazil Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 99 Brazil Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 100 Argentina Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 101 Argentina Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 102 Argentina Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 103 Argentina Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 104 Middle East & Africa Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 105 Middle East & Africa Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 106 Middle East & Africa Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 107 Middle East & Africa Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 108 Middle East & Africa Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 109 South Africa Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 110 South Africa Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 111 South Africa Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 112 South Africa Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 113 Saudi Arabia Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 114 Saudi Arabia Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 115 Saudi Arabia Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 116 Saudi Arabia Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 117 UAE Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 118 UAE Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 119 UAE Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 120 UAE Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 121 Kuwait Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 122 Kuwait Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 123 Kuwait Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 124 Kuwait Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Naltrexone and buprenorphine market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Naltrexone and buprenorphine market dynamics
Fig. 12 Naltrexone and buprenorphine market: Porter's five forces analysis
Fig. 13 Naltrexone and buprenorphine market: PESTLE analysis
Fig. 14 Product market, 2021 - 2033 (USD Million)
Fig. 15 Naltrexone market, 2021 - 2033 (USD Million)
Fig. 16 Buprenorphine market, 2021 - 2033 (USD Million)
Fig. 17 BELBUCA market, 2021 - 2033 (USD Million)
Fig. 18 Sublocade market, 2021 - 2033 (USD Million)
Fig. 19 Suboxone market, 2021 - 2033 (USD Million)
Fig. 20 Zubsolv market, 2021 - 2033 (USD Million)
Fig. 21 Others market, 2021 - 2033 (USD Million)
Fig. 22 Route of Administration market, 2021 - 2033 (USD Million)
Fig. 23 Naltrexone market, 2021 - 2033 (USD Million)
Fig. 24 Oral Administration market, 2021 - 2033 (USD Million)
Fig. 25 Injectable Administration market, 2021 - 2033 (USD Million)
Fig. 26 Implantable Administration market, 2021 - 2033 (USD Million)
Fig. 27 Buprenorphine market, 2021 - 2033 (USD Million)
Fig. 28 Oral Administration market, 2021 - 2033 (USD Million)
Fig. 29 Injectable Administration market, 2021 - 2033 (USD Million)
Fig. 30 Implantable Administration market, 2021 - 2033 (USD Million)
Fig. 31 Application market, 2021 - 2033 (USD Million)
Fig. 32 Naltrexone market, 2021 - 2033 (USD Million)
Fig. 33 Opioid use disorder (OUD) market, 2021 - 2033 (USD Million)
Fig. 34 Alcohol use disorder (AUD) market, 2021 - 2033 (USD Million)
Fig. 35 Buprenorphine market, 2021 - 2033 (USD Million)
Fig. 36 Opioid use disorder (OUD) market, 2021 - 2033 (USD Million)
Fig. 37 Distribution Channel market, 2021 - 2033 (USD Million)
Fig. 38 Hospital Pharmacies market, 2021 - 2033 (USD Million)
Fig. 39 Retail Pharmacies market, 2021 - 2033 (USD Million)
Fig. 40 Others market, 2021 - 2033 (USD Million)
Fig. 41 Naltrexone and buprenorphine market revenue, by region
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 North America Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 44 U.S. country dynamics
Fig. 45 U.S. Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 46 Canada country dynamics
Fig. 47 Canada Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 48 Mexico country dynamics
Fig. 49 Mexico Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 50 Europe Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 51 UK country dynamics
Fig. 52 UK Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 53 Germany country dynamics
Fig. 54 Germany Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 55 France country dynamics
Fig. 56 France Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 57 Italy country dynamics
Fig. 58 Italy Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 59 Spain country dynamics
Fig. 60 Spain Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 61 Norway country dynamics
Fig. 62 Norway Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 63 Sweden country dynamics
Fig. 64 Sweden Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 65 Denmark country dynamics
Fig. 66 Denmark Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 67 Asia Pacific Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 68 Japan country dynamics
Fig. 69 Japan Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 70 China country dynamics
Fig. 71 China Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 72 India country dynamics
Fig. 73 India Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 74 Australia country dynamics
Fig. 75 Australia Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 76 South Korea country dynamics
Fig. 77 South Korea Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 78 Thailand country dynamics
Fig. 79 Thailand Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 80 Latin America Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 81 Brazil country dynamics
Fig. 82 Brazil Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 83 Argentina country dynamics
Fig. 84 Argentina Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 85 MEA Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 86 South Africa country dynamics
Fig. 87 South Africa Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 88 Saudi Arabia country dynamics
Fig. 89 Saudi Arabia Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 90 UAE country dynamics
Fig. 91 UAE Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 92 Kuwait country dynamics
Fig. 93 Kuwait Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 94 Company categorization
Fig. 95 Company market position analysis
Fig. 96 Strategic framework

Product Code: GVR-4-68040-342-4

Naltrexone And Buprenorphine Market Summary

The global naltrexone and buprenorphine market size was estimated at USD 4.17 billion in 2024 and is projected to reach USD 9.80 billion by 2033, growing at a CAGR of 9.25% from 2025 to 2033. The market is expected to grow due to the increasing prevalence of substance use disorders and greater awareness of opioid use disorder treatments. Government initiatives are further increasing access to advanced addiction care solutions.

WHO Updates Opioid Treatment Guidelines

In February 2025, The World Health Organization (WHO) updated its guidelines on opioid dependence treatment and overdose prevention to expand access to effective interventions. The revised guidelines emphasized the importance of using opioid agonist maintenance treatment (OAMT) with methadone or buprenorphine as the most effective therapy for opioid dependence. WHO also recommended making naloxone more widely available to prevent overdose-related deaths, especially in community settings. The new guidance called for reducing regulatory barriers and increasing investment in harm-reduction services. Additionally, the update urged healthcare providers to deliver evidence-based, person-centered, and non-discriminatory care. These recommendations were aimed at supporting countries in addressing rising opioid-related health challenges and enhancing public health outcomes globally.

Global Naltrexone And Buprenorphine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global naltrexone and buprenorphine market report based on product, route of administration, application, distribution channel, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Naltrexone
Buprenorphine
- BELBUCA
- Sublocade
- Suboxone
- Zubsolv
- Others
Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
Naltrexone
- Oral Administration
- Injectable Administration
- Implantable Administration
Buprenorphine
- Oral Administration
- Injectable Administration
- Implantable Administration
Application Outlook (Revenue, USD Million, 2021 - 2033)
Naltrexone
- Opioid use disorder (OUD)
- Alcohol use disorder (AUD
Buprenorphine
- Opioid use disorder (OUD)
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
Hospitals Pharmacies
Retail Pharmacies
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. Route of Administration
- 1.2.3. Application
- 1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis

Chapter 4. Naltrexone and Buprenorphine Market: Product Business Analysis

4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Naltrexone
- 4.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
4.5. Buprenorphine
- 4.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
- 4.5.2. BELBUCA
  - 4.5.2.1. BELBUCA Market, 2021 - 2033 (USD Million)
- 4.5.3. Sublocade
  - 4.5.3.1. Sublocade Market, 2021 - 2033 (USD Million)
- 4.5.4. Suboxone
  - 4.5.4.1. Suboxone Market, 2021 - 2033 (USD Million)
- 4.5.5. Zubsolv
  - 4.5.5.1. Zubsolv Market, 2021 - 2033 (USD Million)
- 4.5.6. Others
  - 4.5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Naltrexone and Buprenorphine Market: Route of Administration Business Analysis

5.1. Route of Administration Market Share, 2024 & 2033
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
5.4. Naltrexone
- 5.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
- 5.4.2. Oral Administration
  - 5.4.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
- 5.4.3. Injectable Administration
  - 5.4.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
- 5.4.4. Implantable Administration
  - 5.4.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)
5.5. Buprenorphine
- 5.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
- 5.5.2. Oral Administration
  - 5.5.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
- 5.5.3. Injectable Administration
  - 5.5.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
- 5.5.4. Implantable Administration
  - 5.5.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)

Chapter 6. Naltrexone and Buprenorphine Market: Application Business Analysis

6.1. Application Market Share, 2024 & 2033
6.2. Application Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Naltrexone
- 6.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
- 6.4.2. Opioid use disorder (OUD)
  - 6.4.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)
- 6.4.3. Alcohol use disorder (AUD)
  - 6.4.3.1. Alcohol use disorder (AUD) Market, 2021 - 2033 (USD Million)
6.5. Buprenorphine
- 6.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
- 6.5.2. Opioid use disorder (OUD)
  - 6.5.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)

Chapter 7. Naltrexone and Buprenorphine Market: Distribution Channel Business Analysis

7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
7.6. Others
- 7.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
- 8.4.1. North America Naltrexone and Buprenorphine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
- 8.4.2. U.S.
  - 8.4.2.1. Key Country Dynamics
  - 8.4.2.2. End Use Disease Prevalence
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. Reimbursement Framework
  - 8.4.2.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.3. Canada
  - 8.4.3.1. Key Country Dynamics
  - 8.4.3.2. End Use Disease Prevalence
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Reimbursement Framework
  - 8.4.3.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.4.4. Mexico
  - 8.4.4.1. Key Country Dynamics
  - 8.4.4.2. End Use Disease Prevalence
  - 8.4.4.3. Regulatory Framework
  - 8.4.4.4. Reimbursement Framework
  - 8.4.4.5. Mexico Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
- 8.5.1. Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.2. UK
  - 8.5.2.1. Key Country Dynamics
  - 8.5.2.2. End Use Disease Prevalence
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Reimbursement Framework
  - 8.5.2.5. Uk Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.3. Germany
  - 8.5.3.1. Key Country Dynamics
  - 8.5.3.2. End Use Disease Prevalence
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. Reimbursement Framework
  - 8.5.3.5. Germany Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.4. France
  - 8.5.4.1. Key Country Dynamics
  - 8.5.4.2. End Use Disease Prevalence
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. Reimbursement Framework
  - 8.5.4.5. France Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.5. Italy
  - 8.5.5.1. Key Country Dynamics
  - 8.5.5.2. End Use Disease Prevalence
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Reimbursement Framework
  - 8.5.5.5. Italy Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.6. Spain
  - 8.5.6.1. Key Country Dynamics
  - 8.5.6.2. End Use Disease Prevalence
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Reimbursement Framework
  - 8.5.6.5. Spain Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.7. Denmark
  - 8.5.7.1. Key Country Dynamics
  - 8.5.7.2. End Use Disease Prevalence
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Reimbursement Framework
  - 8.5.7.5. Denmark Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.8. Sweden
  - 8.5.8.1. Key Country Dynamics
  - 8.5.8.2. End Use Disease Prevalence
  - 8.5.8.3. Regulatory Framework
  - 8.5.8.4. Reimbursement Framework
  - 8.5.8.5. Sweden Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.5.9. Norway
  - 8.5.9.1. Key Country Dynamics
  - 8.5.9.2. End Use Disease Prevalence
  - 8.5.9.3. Regulatory Framework
  - 8.5.9.4. Reimbursement Framework
  - 8.5.9.5. Norway Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Asia Pacific Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.2. Japan
  - 8.6.2.1. Key Country Dynamics
  - 8.6.2.2. End Use Disease Prevalence
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. Reimbursement Framework
  - 8.6.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.3. China
  - 8.6.3.1. Key Country Dynamics
  - 8.6.3.2. End Use Disease Prevalence
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. Reimbursement Framework
  - 8.6.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.4. India
  - 8.6.4.1. Key Country Dynamics
  - 8.6.4.2. End Use Disease Prevalence
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. Reimbursement Framework
  - 8.6.4.5. India Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.5. Australia
  - 8.6.5.1. Key Country Dynamics
  - 8.6.5.2. End Use Disease Prevalence
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. Reimbursement Framework
  - 8.6.5.5. Australia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.6. South Korea
  - 8.6.6.1. Key Country Dynamics
  - 8.6.6.2. End Use Disease Prevalence
  - 8.6.6.3. Regulatory Framework
  - 8.6.6.4. Reimbursement Framework
  - 8.6.6.5. South Korea Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.6.7. Thailand
  - 8.6.7.1. Key Country Dynamics
  - 8.6.7.2. End Use Disease Prevalence
  - 8.6.7.3. Regulatory Framework
  - 8.6.7.4. Reimbursement Framework
  - 8.6.7.5. Thailand Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
- 8.7.1. Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.2. Brazil
  - 8.7.2.1. Key Country Dynamics
  - 8.7.2.2. End Use Disease Prevalence
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. Reimbursement Framework
  - 8.7.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.7.3. Argentina
  - 8.7.3.1. Key Country Dynamics
  - 8.7.3.2. End Use Disease Prevalence
  - 8.7.3.3. Regulatory Framework
  - 8.7.3.4. Reimbursement Framework
  - 8.7.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.2. South Africa
  - 8.8.2.1. Key Country Dynamics
  - 8.8.2.2. End Use Disease Prevalence
  - 8.8.2.3. Regulatory Framework
  - 8.8.2.4. Reimbursement Framework
  - 8.8.2.5. South Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.3. Saudi Arabia
  - 8.8.3.1. Key Country Dynamics
  - 8.8.3.2. End Use Disease Prevalence
  - 8.8.3.3. Regulatory Framework
  - 8.8.3.4. Reimbursement Framework
  - 8.8.3.5. Saudi Arabia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.4. UAE
  - 8.8.4.1. Key Country Dynamics
  - 8.8.4.2. End Use Disease Prevalence
  - 8.8.4.3. Regulatory Framework
  - 8.8.4.4. Reimbursement Framework
  - 8.8.4.5. UAE Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 8.8.5. Kuwait
  - 8.8.5.1. Key Country Dynamics
  - 8.8.5.2. End Use Disease Prevalence
  - 8.8.5.3. Regulatory Framework
  - 8.8.5.4. Reimbursement Framework
  - 8.8.5.5. Kuwait Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
- 9.5.1. Indivior PLC
  - 9.5.1.1. Overview
  - 9.5.1.2. Financial Performance
  - 9.5.1.3. Product Benchmarking
  - 9.5.1.4. Strategic Initiatives
- 9.5.2. Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)
  - 9.5.2.1. Overview
  - 9.5.2.2. Financial Performance
  - 9.5.2.3. Product Benchmarking
  - 9.5.2.4. Strategic Initiatives
- 9.5.3. Alkermes, Inc.
  - 9.5.3.1. Overview
  - 9.5.3.2. Financial Performance
  - 9.5.3.3. Product Benchmarking
  - 9.5.3.4. Strategic Initiatives
- 9.5.4. Orexo US, Inc. (a part of Orexo AB)
  - 9.5.4.1. Overview
  - 9.5.4.2. Financial Performance
  - 9.5.4.3. Product Benchmarking
  - 9.5.4.4. Strategic Initiatives
- 9.5.5. Titan Pharmaceuticals, Inc.
  - 9.5.5.1. Overview
  - 9.5.5.2. Financial Performance
  - 9.5.5.3. Product Benchmarking
  - 9.5.5.4. Strategic Initiatives
- 9.5.6. Omeros Corporation
  - 9.5.6.1. Overview
  - 9.5.6.2. Financial Performance
  - 9.5.6.3. Product Benchmarking
  - 9.5.6.4. Strategic Initiatives
- 9.5.7. Camurus
  - 9.5.7.1. Overview
  - 9.5.7.2. Financial Performance
  - 9.5.7.3. Product Benchmarking
  - 9.5.7.4. Strategic Initiatives
- 9.5.8. Sun Pharmaceutical Industries Ltd
  - 9.5.8.1. Overview
  - 9.5.8.2. Financial Performance
  - 9.5.8.3. Product Benchmarking
  - 9.5.8.4. Strategic Initiatives

ナルトレキソンとブプレノルフィンの市場規模、シェア、動向分析レポート：製品別、投与経路別、用途別、流通チャネル別、地域別、セグメント別予測、2025年～2033年

Naltrexone And Buprenorphine Market Size, Share & Trends Analysis Report By Product (Naltrexone, Buprenorphine), By Route Of Administration, By Application, By Distribution Channel (Hospitals Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

目次

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章ナルトレキソンとブプレノルフィン市場の変数、動向、範囲

第4章ナルトレキソンとブプレノルフィン市場：製品ビジネス分析

第5章ナルトレキソンとブプレノルフィン市場：投与経路ビジネス分析

第6章ナルトレキソンとブプレノルフィン市場：用途ビジネス分析

第7章ナルトレキソンとブプレノルフィン市場：流通チャネルビジネス分析

第8章ナルトレキソンとブプレノルフィン市場：地域別、推定・動向分析

第9章競合情勢

List of Tables

List of Figures

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, & Scope

Chapter 4. Naltrexone and Buprenorphine Market: Product Business Analysis

Chapter 5. Naltrexone and Buprenorphine Market: Route of Administration Business Analysis

Chapter 6. Naltrexone and Buprenorphine Market: Application Business Analysis

Chapter 7. Naltrexone and Buprenorphine Market: Distribution Channel Business Analysis

Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

ナルトレキソンとブプレノルフィンの市場規模、シェア、動向分析レポート：製品別、投与経路別、用途別、流通チャネル別、地域別、セグメント別予測、2025年～2033年

Naltrexone And Buprenorphine Market Size, Share & Trends Analysis Report By Product (Naltrexone, Buprenorphine), By Route Of Administration, By Application, By Distribution Channel (Hospitals Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ナルトレキソンとブプレノルフィン市場の変数、動向、範囲

第4章 ナルトレキソンとブプレノルフィン市場：製品ビジネス分析

第5章 ナルトレキソンとブプレノルフィン市場：投与経路ビジネス分析

第6章 ナルトレキソンとブプレノルフィン市場：用途ビジネス分析

第7章 ナルトレキソンとブプレノルフィン市場：流通チャネルビジネス分析

第8章 ナルトレキソンとブプレノルフィン市場：地域別、推定・動向分析

第9章 競合情勢

List of Tables

List of Figures

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, & Scope

Chapter 4. Naltrexone and Buprenorphine Market: Product Business Analysis

Chapter 5. Naltrexone and Buprenorphine Market: Route of Administration Business Analysis

Chapter 6. Naltrexone and Buprenorphine Market: Application Business Analysis

Chapter 7. Naltrexone and Buprenorphine Market: Distribution Channel Business Analysis

Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates & Trend Analysis

Chapter 9. Competitive Landscape

第1章調査手法と範囲

第2章エグゼクティブサマリー

第3章ナルトレキソンとブプレノルフィン市場の変数、動向、範囲

第4章ナルトレキソンとブプレノルフィン市場：製品ビジネス分析

第5章ナルトレキソンとブプレノルフィン市場：投与経路ビジネス分析

第6章ナルトレキソンとブプレノルフィン市場：用途ビジネス分析

第7章ナルトレキソンとブプレノルフィン市場：流通チャネルビジネス分析

第8章ナルトレキソンとブプレノルフィン市場：地域別、推定・動向分析

第9章競合情勢